Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,245.50up ₹61.10 (5.16%)BSE ₹1,244.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,184.40.
30 Oct: open ₹1,190.00, high ₹1,248.90, low ₹1,182.00
52-week range of traded prices to 30 Oct 2026
₹835.50Low, 2 Apr 2026₹1,248.90High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,24,239 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.53
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 24.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,60,70935.2% delivered
Zydus Lifesciences share news and announcements
1,762 announcements, routine notices left out, newest first. Page 29 of 36.
Jun 2015
May 2015
21 May · Legal
Exchange has sought clarification from Cadila Healthcare Limited with respect to recent news item captioned "Cadila Eyes Claris Arm for Rs. 3,400 Cr". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.20 May · Disclosure of Voting Pattern - Clause 35A
16 May · Code of Conduct under SEBI(PIT) Reg., 2015
15 May · Dividend
Board of Directors of the Company at its meeting held on May 15, 2015 have recommended a dividend of Rs 12/- (@ 240%) per equity share on 204,748,520 equity shares of Rs 5/- each for the financial year ended on March 31, 2015.
Apr 2015
27 Apr · Board meeting
To consider amongst other agenda items: 1. To approve the audited stand-alone and consolidated financial results for the quarter / year ended on March 31, 2015 2. To recommend the dividend on equity shares of the Company for the financial year ended on March 31, 2015.
Mar 2015
Feb 2015
Jan 2015
20 Jan · Board meeting
To consider amongst other agenda items to approve the unaudited financial results for the quarter and nine months ended on December 31, 2014.
Dec 2014
31 Dec · Legal
Exchange had sought clarification from Cadila Healthcare Limited with respect to a news item captioned "Wockhardt, Cadila & Hospira Voluntarily Recall Drugs in US". The Company has clarified that "The recall by our US subsidiary was voluntary and a class-III type recall, which means that the use of the product is not likely to cause any adverse health consequences. There is no material impact".31 Dec · Legal
Exchange has sought clarification from Cadila Healthcare Limited with respect to recent news item captioned "Wockhardt, Cadila & Hospira Voluntarily Recall Drugs in US". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.31 Dec · Updates
During an interaction with a media person, the Company's Chairman and Managing Director was asked about healthcare concerns caused by "Congo Virus" and "Ebola Virus" and he had responded by saying that group was developing vaccines for these diseases as a part of Company's vaccine development programme. There were no investment details shared during the interaction.29 Dec · Updates
17 Dec · Legal
Exchange has sought clarification from Cadila Healthcare Limited with respect to recent news item captioned "Cadila's US arm recalls 63,648 bottles of benzonatate capsules". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.4 Dec · Management
Directors of the Company vide circular resolution approved the resignation of Shri Apurva S . Diwanji.
Nov 2014
Oct 2014
21 Oct · Legal
Exchange had sought clarification from Cadila Healthcare Limited with respect to a news item captioned "Cadila Healthcare recalls hypertension drug in US". The Company has clarified that The news are correct, but Cadila Healthcare Limited does not envisage any impact of the same . .20 Oct · Legal
Exchange has sought clarification from Cadila Healthcare Limited with respect to recent news item captioned "Cadila Healthcare recalls hypertension drug in US". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.13 Oct · Board meeting
To consider amongst other agenda items to approve the unaudited financial results for the quarter/ half-year ended on September 30, 2014. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 1992, the Trading Window will remain close from October 27, 2014 to November 07, 2014 for all directors and designated officers of the Company.10 Oct · Legal
Exchange had sought clarification from Cadila Healthcare Limited has informed with respect to a news item captioned "Sun, Dr Reddy's, cadila named in US Congress price probe". The Company has clarified that "We confirm that our US subsidiary company has received recently a data request from US Congress relating to the price increase of 2 products being distributed by Zydus subsidiary in the US market. The article has no material impact on the Company".
Sep 2014
Aug 2014
8 Aug · Meeting